Global Monoclonal Antibody Therapy Market Growth (Status and Outlook) 2023-2029

Global Monoclonal Antibody Therapy Market Growth (Status and Outlook) 2023-2029

Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.



Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.

LPI (LP Information)' newest research report, the “Monoclonal Antibody Therapy Industry Forecast” looks at past sales and reviews total world Monoclonal Antibody Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibody Therapy sales for 2023 through 2029. With Monoclonal Antibody Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibody Therapy industry.

This Insight Report provides a comprehensive analysis of the global Monoclonal Antibody Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Monoclonal Antibody Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Monoclonal Antibody Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibody Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibody Therapy.

The global Monoclonal Antibody Therapy market size is projected to grow from US$ 111700 million in 2022 to US$ 183700 million in 2029; it is expected to grow at a CAGR of 7.4% from 2023 to 2029.

The industry's leading producers are Roche, Abbvie and J & J, with revenues of 15.61%, 12.10% and 10.05% in 2019.

This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibody Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Human Monoclonal Antibody
Humanized Monoclonal Antibody
Chimeric Monoclonal Antibody
Murine Monoclonal Antibody

Segmentation by application
Cancer
Autoimmune Diseases
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbvie
Amgen
Glaxosmithkline
Merck
Novartis
Roche
Johson & Johson
Novartis

Please note: The report will take approximately 2 business days to prepare and deliver.